CV Lattes
ResearcherID
ORCID
Google Scholar Citations
Universidade de São Paulo (USP). Instituto de Ciências Biomédicas (ICB) (Institutional affiliation from the last research proposal) Birthplace: Espanha
Holds a degree in Veterinary Medicine from the Universidad de Zaragoza (2016), with the diploma revalidated by the Universidade Estadual do Norte Fluminense Darcy Ribeiro (2025). Completed a Master's degree (2019) and a PhD (2023) in Sciences within the "Biology of Host-Pathogen Interaction" program at the University of São Paulo (USP). During the PhD, conducted a research internship abroad at the Universitat Politècnica de Catalunya, Spain, subsequently having the doctoral diploma revalidated by the University of Barcelona (2023).Currently, pursuing a postdoctoral fellowship at the Institute of Biomedical Sciences, USP (started in 2023), with an international exchange in the "Mitochondrial Regulation of Cell Death and Steatohepatitis" group at the Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), in Barcelona.The research focuses on the study of isoprenoid metabolism as a therapeutic strategy for cancer, metabolic diseases, and parasitic infections, particularly those caused by Plasmodium falciparum and Leishmania spp. Specifically dedicated to investigating the metabolism of isoprenoid alcohols, the ubiquinone biosynthesis pathway, cellular bioenergetics, and the pharmacological inhibition of isoprenylated product biosynthesis.Has experience in the fields of Biochemistry and Molecular Biology, with an emphasis on the Biochemistry of Microorganisms and Tumor Cells. (Source: Lattes Curriculum)
| News published in Agência FAPESP Newsletter about the researcher |
| More itemsLess items |
| TITULO |
| Articles published in other media outlets ( ): |
| More itemsLess items |
| VEICULO: TITULO (DATA) |
| VEICULO: TITULO (DATA) |
Plasmodium falciparum is the etiologic agent of human falciform malaria, one of the most prevalent diseases in tropical and subtropical regions of the world. One of the largest problems for controlling the disease is the emergence of drug resistance, which leads to the need for discovering new antimalarial compounds and creating new effective pharmaceutical combinations. One of the most s…
Resistances to the different etiological treatments used for malaria have already arisen and so it is necessary to find new compounds and effective pharmaceutical combinations totreat this disease. One of the most recently discovered antimalarials is atovaquone (ATO), an effective competitive inhibitor with ubiquinol or reduced coenzyme Q (UQH2) for its binding in the mitochondrial bc1 co…
Malignant tertian malaria is a human disease caused by the Plasmodium falciparum parasite. The World Health Organization estimated that in 2015 from 149 million to 303 million people were affected by malaria,from which approximately 438,000 died. Most deaths occur in children and pregnant women. A resistance has already emerged to drugs currently being used. As a result of this it is nece…
In animals, the mevalonate (MVA) pathway is the primary source of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). The MVA pathway is crucial for cholesterol biosynthesis and the prenylation of Ras and Rho oncoproteins, besides several other processes. Therefore, dysregulation of the MVA pathway is associated with hypercholesterolemia, oncogenesis, and other metabolic…
One of the most promising targets for malaria drug design is the isoprenoid metabolism. Isoprenoid biosynthesis depends on the methylerythritol 4-phosphate (MEP) pathway, located in a modified plastid organelle called apicoplast. Isoprenoids produced by this pathway are used for isoprenylation of several metabolites and proteins. Former observations from our group demonstrated the plasmod…
| 3 / 3 | Completed scholarships in Brazil |
| 1 / 1 | Ongoing scholarships abroad |
| 1 / 1 | Completed scholarships abroad |
| 5 / 5 | All Scholarships |
| Associated processes | |